Clinical Trials
143 trialsA Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer
IRCCS San Raffaele
LEARN
University of Sydney
KCC-S
University of Utah
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Istituto Oncologico Veneto IRCCS
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
University Health Network, Toronto
iCaRe2
University of Nebraska
TDM for Optimized Outcome in Patients With mRCC.
University of Aarhus
FRISC
Centre Hospitalier Universitaire, Amiens
BIOSUNTOX
University Hospital, Rouen
RCCETT
Peking University Third Hospital
Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
SMART
University of Alberta
Kidney Cancer DNA Registry
Memorial Sloan Kettering Cancer Center
NEPHRAMBU
GCS Ramsay Santé pour l'Enseignement et la Recherche
PP-RECURK
Gødstrup Hospital
KIDCaD
Charles University, Czech Republic
SPECT/CT for the Characterization of Renal Masses
Jonsson Comprehensive Cancer Center
DISSRM
Abramson Cancer Center at Penn Medicine
OCCURORTW
Jagiellonian University
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
Mayo Clinic
WASHOUT
British Urology Researchers in Surgical Training
COSTAR
Peking University First Hospital
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial
Istituto Clinico Humanitas
Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
COSMO
Harvard Medical School (HMS and HSDM)
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
Palo Alto Veterans Institute for Research
AI for Renal Tumors Using Non-Contrast CT
Fudan University
IMPLICATION
Centre Hospitalier Universitaire de Besancon
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Jinling Hospital, China
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Jinling Hospital, China
GenCInibs-Suni
Centre Hospitalier Universitaire de Nīmes
Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
LIBERATE
University Health Network, Toronto
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
The University of Texas Health Science Center at San Antonio
Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
University of Texas Southwestern Medical Center
UroCCR
University Hospital, Bordeaux
Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
Memorial Sloan Kettering Cancer Center
(3D) Ultrasound Imaging Liver and Kidney
Western University, Canada
RUPTURE
Azienda Ospedaliera Universitaria Integrata Verona
PRIORITY
Institut Bergonié
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
Centre of Postgraduate Medical Education
PRO-RCC
PROspective Renal Cancer Cohort Foundation
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
The First Affiliated Hospital of Xiamen University
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
SOGUGCOVID
Spanish Oncology Genito-Urinary Group
Optimising Renal Tumour Management Through Artificial Intelligence Modules
The First Affiliated Hospital with Nanjing Medical University
SPECTRE
IRCCS Azienda Ospedaliero-Universitaria di Bologna
EVIDENT
Sheffield Teaching Hospitals NHS Foundation Trust